Progress in the adjuvant treatment of colon cancer - Has it influenced clinical practice?

被引：29

作者：

Van Cutsem, E ^{[1
]}

Costa, F

机构：

[1] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium

[2] Hosp Sirio ZLibanes, Ctr Oncol, Sao Paulo, Brazil

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2005年 / 294卷 / 21期

关键词：

D O I：

10.1001/jama.294.21.2758

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2758 / 2760

页数：3

共 24 条

[21] Estimating the world cancer burden: GLOBOCAN 2000 [J].

Parkin, DM ;

Bray, F ;

Ferlay, J ;

Pisani, P .

INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (02) :153-156

[22] Capecitabine as adjuvant treatment for stage III colon cancer [J].

Twelves, C ;

Wong, A ;

Nowacki, MP ;

Abt, M ;

Burris, H ;

Carrato, A ;

Cassidy, J ;

Cervantes, A ;

Fagerberg, J ;

Georgoulias, V ;

Husseini, F ;

Jodrell, D ;

Koralewski, P ;

Kröning, H ;

Maroun, J ;

Marschner, N ;

McKendrick, J ;

Pawlicki, M ;

Rosso, R ;

Schüller, J ;

Seitz, JF ;

Stabuc, B ;

Tujakowski, J ;

Van Hazel, G ;

Zaluski, J ;

Scheithauer, W .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (26) :2696-2704

[23] Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients [J].

Westra, JL ;

Schaapveld, M ;

Hollema, H ;

de Boer, JP ;

Kraak, MMJ ;

de Jong, D ;

ter Elst, A ;

Mulder, NH ;

Buys, CHCM ;

Hofstra, RMW ;

Plukker, JTM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5635-5643

[24]

WOLMARK N, 2005, ANN M AM SOC CLIN ON

← 1 2 3 →